|
References
1. Soriano V, Puoti M, Sulkowski M, et al. Care of patients
with hepatitis C and HIV co-infection. Update recommendations
from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
2. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect
of antiretroviral therapy on liver-related mortality in patients
with HIV and hepatitis C coinfection. Lancet 2003; 362:1708-13.
3. Mehta SH, Thomas DL, Torbenson M, et al. The effect of
antiretroviral therapy on liver disease among adults with
HIV and hepatitis C coinfection. Hepatology 2005; 41:123-31.
4. Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients
with HIV infection and viral hepatitis B or C: a cohort study.
AIDS 2004; 18:2039-45.
5. Puoti M, Cozzi-Lepri A, Ancarani F, et al. The management
of hepatitis B virus/HIV-1 co-infected patients starting their
first HAART regimen. Treating two infections for the price
of one drug? Antivir Ther. 2004; 9:811-7.
6. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of
viral hepatitis co-infection on response to antiretroviral
therapy and HIV disease progression in the HIV-NAT cohort.
AIDS 2004; 18:1169-77.
7. Nuñez M, Soriano V. Hepatotoxicity of antiretrovirals.
Incidence, mechanisms and management. Drug safety 2005; 28:53-66.
8. Locarnini S, Hatzakis A, Heathcote J, et al. Management
of antiviral resistance in patients with chronic hepatitis
B. Antivir Ther 2004; 9:679-93.
9. Castéra L, Vergniol J, Foucher J, et al. Prospective
comparison of transient elastography, Fibrotest, APRI, and
liver biopsy for the assessment of fibrosis in chronic hepatitis
C. Gastroenterology 2005; 128:343-350.
10. Keeffe E, Dieterich D, Han S-H, et al. A treatment algorithm
for the management of chronic hepatitis B virus infection
in the United States. Clin Gastroenterol Hepatology 2004;
2: 87-106.
11. Soriano V, Puoti M, Bonacini M, et al. Care of patients
with chronic hepatitis B and HIV co-infection: recommendations
from an HIV-HBV International Panel. AIDS. 2005; 19:221-240.
12. Benhamou Y, Domínguez S, Quioc J, et al. Effect
of HIV infection on Chronic hepatitis B-related liver decompensation.
Abstract 933. 12th Conference on Retroviruses and Opportunistic
Infections. February 22-25, 2005. Boston, MA.
13. Nuñez M, Puoti M, Camino N, Soriano V. Treatment
of chronic hepatitis B in the HIV-infected patient: present
and future. Clin Infect Dis 2003; 37: 1678-1685.
14. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of
chronic hepatitis B virus (HBV) infection in coinfected patients
receiving lamivudine as a component of anti-human immunodeficiency
virus regimens. Clin Infect Dis. 2001; 32:963-9.
15. Nelson M, Portsmouth S, Stebbing J, et al. An open-label
study of tenofovir in HIV-1 and Hepatitis B virus co-infected
individuals. AIDS. 2003; 17:F7-10.
16. Benhamou Y, Thibault V, Vig P, et al. Long-term treatment
with adefovir dipivoxil (ADV) for three years in patients
with lamivudine-resistant (LAM-R) HBV and HIV coinfection
results in significant and sustained clinical improvement.
Hepatology 2003; 38 (Suppl 1): 714A [Abstract 1158]
17. Marcellin P, Lau G, Bonino F, et al. Peginterferon alfa-2a
alone, lamivudine alone, and the two in combination in patients
with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;
351:1206-1217.
18. Janssen H, Zonneveld M, Senturk H, et al. Pegylated interferon
alfa-2b alone or in combination with lamivudine for HbeAg-positive
chronic hepatitis B: a randomized trial. Lancet 2005; 365:
123-9.
19. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon
Alfa-2a plus ribavirin for chronic hepatitis C virus infection
in HIV-infected patients. N Engl J Med 2004; 351:438-50.
20. Chung R, Andersen J, Volberding P, et al. Peginterferon
Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin
for chronic hepatitis C in HIV-coinfected persons. N Engl
J Med 2004; 351:451-9.
21. Laguno M, Murillas J, Blanco JL, et al. Peginterferon
alfa-2b plus ribavirin compared with interferon alfa-2b plus
ribavirin for treatment of HIV/HCV co-infected patients. AIDS
2004; 18: F27-36.
22. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon
alfa-2b vs standard interferon alfa-2b, plus ribavirin, for
chronic hepatitis C in HIV-infected patients. JAMA 2004; 292:
2839-48.
23. Mauss S, Valenti W, DePamphilis J, et al. Risk factors
for hepatic decompensation in patients with HIV/HCV coinfection
and liver cirrosis during interferon therapy. AIDS 2004; 18:F21-5
24. Sulkowski M, and others. Unexpected Significant Liver
Disease among HIV/HCV-co-infected Persons with Minimal Fibrosis
on Initial Liver Biopsy Abstract 121. 12th Conference on Retroviruses
and Opportunistic Infections. February 22-25, 2005. Boston,
MA.
25. Fleming C, Craven D, Thornton D, Tumilty S, Nunes D. Hepatitis
C virus and HIV coinfection in an urban population: low eligibility
for interferon treatment. Clin Infect Dis 2003; 36:97-100.
26. Rauch A, Egger M, Reichen J, Furrer H; Swiss HIV Cohort
Study. J Acquir Immune Defic Syndr 2005; 38:238-240.
27. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon-alpha2a
and ribavirin combination therapy in chronic hepatitis C:
a randomized study of treatment duration and ribavirin dose.
Ann Intern Med 2004; 140:I67.
28. Rendón A, and others. Ribavirin plasma concentrations
predict early virological response as well as anemia in anti-hepatitis
therapy. Abstract 929. 12th Conference on Retroviruses and
Opportunistic Infections. February 22-25, 2005. Boston, MA.
29. Breilh D, and others. Plasma target concentration of ribavirin
in HCV/HIV-co-infected patients. Abstract 928. 12th Conference
on Retroviruses and Opportunistic Infections. February 22-25,
2005. Boston, MA.
30. Perez-Olmeda M, Nuñez M, Romero M, et al. Pegylated
IFN-a2b plus ribavirin as therapy for chronic hepatitis C
in HIV-infected patients. AIDS 2003; 17: 1023-8.
31. National Institutes of Health Consensus Development Conference
Statement: Management of hepatitis C. Hepatology 2002; 36:3-20.
32. Afdhal N, Dieterich D, Pockros P, et al. Epoetin alfa
maintains ribavirin dose in HCV-infected patients. A prospective,
double-blind randomized controlled study. Gastroenterology
2004; 126:1302-11.
33. Gish R, Arora S, Nelson D, Fernández H, Lamon K.
Safety and efficacy of viramidine in combination with pegylated
interferon alfa-2a for treatment of hepatitis C in therapy-naïve
patients. J Hep 2004; 40 (Suppl 1):141-2 [Abstract 479]
34. Chaix ML, and others. Homosexually Transmitted HCV Acute
Infection Related to a Clustered Genotype 4 HCV in HIV-1-infected
Men and Inefficacy of Early Antiviral Therapy. Abstract 122.
12th Conference on Retroviruses and Opportunistic Infections.
February 22-25, 2005. Boston, MA.
35. Graham CS, Curry M, He Q, et al. Comparison of HCV-specific
intrahepatic CD4+ T cells in HIV/HCV versus HCV. Hepatology.
2004; 40:125-32.
Back
to Conference Main Page
|
